CG Oncology, Inc. Hits New 52-Week High of $59.95

CG Oncology, Inc. has reached a significant milestone by hitting a new 52-week high of USD 59.95 on February 23, 2026. This achievement marks a notable increase from its 52-week low of USD 14.80, reflecting a remarkable performance over the past year. The stock has demonstrated a robust annual growth rate of 65.56%, significantly outperforming the S&P 500, which recorded a gain of 12.95% during the same period. As a small-cap company in the miscellaneous industry, CG Oncology, Inc. has a market capitalization of approximately USD 4.649 billion. Despite its current loss-making status, indicated by a negative price-to-earnings ratio, the company continues to attract attention due to its impressive stock performance. The company's financial metrics reveal a price-to-book ratio of 6.76 and a return on equity of -22.03%, while it maintains a debt-to-equity ratio of -0.98. With these figures, CG Oncology, Inc. stands out in the market, showcasing its recent upward trajectory.